Impedimed, Inc.

ImpediMed is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices for noninvasive clinical assessment and monitoring of fluid status and tissue composition. The company's flagship SOZO® Digital Health Platform is FDA-cleared and enables real-time measurement of body composition, fluid volumes, and tissue changes across multiple clinical applications. Primary use cases include early detection and monitoring of secondary lymphedema in cancer survivors, heart failure fluid management, medical weight management assessment, and wellness/longevity monitoring. The SOZO platform utilizes advanced BIS technology measuring 256 frequencies to separate intra- and extracellular fluid and deliver actionable insights at point of care. The company operates a cloud-connected SaaS model supporting personalized care monitoring across the patient treatment continuum, with global distribution in US, Europe, Australia, and other markets.